US Stock MarketDetailed Quotes
CYCN Cyclerion Therapeutics
- 1.4500
- +0.0200+1.40%
Close Nov 25 16:00 ET
- 1.5200
- +0.0700+4.83%
Post 17:37 ET
3.93MMarket Cap-680P/E (TTM)
1.5900High1.4400Low107.80KVolume1.5900Open1.4300Pre Close160.73KTurnover7.57%Turnover RatioLossP/E (Static)2.71MShares5.250052wk High0.48P/B2.07MFloat Cap1.270052wk Low--Dividend TTM1.42MShs Float420.0000Historical High--Div YieldTTM10.49%Amplitude1.2700Historical Low1.4910Avg Price1Lot Size
About Cyclerion Therapeutics Company
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Company Profile
SymbolCYCN
Company NameCyclerion Therapeutics
Listing DateMar 18, 2019
Founded2018
CEOMs. Regina Margaret Graul, PhD
MarketNASDAQ
Employees1
Fiscal Year Ends12-31
AddressRiverview II,245 First Street,18th floor
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-857-327-8778
Websitehttp://www.cyclerion.com
Company Executives
- Name
- Position
- Salary
- Rhonda M. Chicko
- Chief Financial Officer and Principal Accounting Officer
- --
- Regina Margaret Graul, PhD
- President and Principal Executive Officer
- 155.33K
- Dr. Peter M. Hecht, PhD
- Director
- 82.95K
- Dr. Steven E. Hyman, M.D.
- Independent Director
- 52.64K
- Dr. Errol B. De Souza,PhD
- Independent Director
- 58.53K
- Dr. Dina Katabi, M.S.,PhD
- Independent Director
- --
- Michael J. Higgins
- Independent Director
- --
- Terrance G. Mcguire
- Independent Director
- 59.03K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data